Dr. Clive Dix, who played a key role in helping pharmaceutical firms create the COVID-19 vaccines, told LBC radio on Jan. 16: “The Omicron variant is a relatively mild virus. And to just keep vaccinating people and thinking of doing it again to protect the population is, in my view, now a waste of time.”
Dix said the focus now should be on protecting vulnerable people, such as those over 60, 2 percent of whom remain unvaccinated.
“We should have a highly-focused approach to get those people vaccinated and anybody else who’s vulnerable,” he said.
Though he supports the ongoing booster campaign, he said he has been “critical” of boosting everybody as he is not convinced “it was needed or is needed” for younger people.
Dix said, “I think the thinking of the time was very much to stop infection and transmission where clearly these vaccines don’t do that.”
He said the government needs to be “very focused” on educating itself for the “future vaccination programme” next winter.
He suggested that an “immune status study” should be conducted to “understand exactly where everybody’s immunity is,” so that “by next winter, we can really have a policy of vaccination that’s educated, using the right vaccines at the right time for the right people.”
“We now need to manage disease, not virus spread,” he said. “So stopping progression to severe disease in vulnerable groups is the future objective.”
Sir Patrick Vallance, the UK’s chief scientific adviser, said on Jan. 3 that it is not the government’s “long-term view” to give everyone a booster vaccine every few months.
Professor Andrew Pollard, director of the Oxford Vaccine Group and chair of the government’s Joint Committee on Vaccination and Immunisation (JCVI), told The Telegraph that it’s “not sustainable or affordable” to “vaccinate the planet every four to six months.”
The JCVI said the three doses of the vaccines are still providing “very good protection against severe disease,” and an immediate second booster dose to the most vulnerable would “provide only limited additional benefit against severe disease at this time.”